The Patent Finder
IB

Igm Biosciences, Inc.

First filing 2005
OverviewNotableFeesChangesFamiliesPatent listSources & methods

20 patents currently held

2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2034. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2034
Next term end
11
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Modified J-Chain US 11,555,075
Cited by 15 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Ends Apr 2035 · High confidence
Also notable
Multimeric Death Domain-Containing RECEPTOR-5 (DR5) Antibodies and Uses Thereof US 10,689,449
Cited by 29 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Ends Jan 2036 · High confidence
Also notable
ANTI-PD-L1 Antibodies US 10,954,302
Cited by 22 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2037.
Ends Sep 2037 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 16, 2027
    The maintenance fee for Constant Chain Modified Bispecific, Penta- and Hexavalent Ig-M Antibodies (US 10,351,631) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
  • 1 fee due Mar 3, 2027
    The maintenance fee for Modified J-Chain (US 10,400,038) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
  • 1 fee due Aug 25, 2027
    The maintenance fee for Multi-Valent Human Immunodeficiency Virus Antigen Binding Molecules and Uses Thereof (US 10,570,191) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
  • 1 fee due Sep 30, 2027
    The maintenance fee for Multi-Valent Hepatitis B Virus Antigen Binding Molecules and Uses Thereof (US 10,604,559) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
  • 1 fee due Oct 14, 2027
    The maintenance fee for Binding Molecules with Modified J-Chain (US 10,618,978) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 10,351,631Constant Chain Modified Bispecific, Penta- and Hexavalent Ig-M Antibodies
In force
 · High confidence
In forceHigh confidence
US 9,951,134Modified J-Chain
In force
 · High confidence
In forceHigh confidence
US 10,400,038Modified J-Chain
In force
 · High confidence
In forceHigh confidence
US 10,975,147Modified J-Chain
In force
 · High confidence
In forceHigh confidence
US 11,555,075Modified J-Chain
In force
 · High confidence
In forceHigh confidence
US 11,639,389Binding Molecules with Modified J-Chain
In force
 · High confidence
In forceHigh confidence
US 9,938,347Tumor Necrosis Factor (TNF) Superfamily Receptor Igm Antibodies and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,689,449Multimeric Death Domain-Containing RECEPTOR-5 (DR5) Antibodies and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,578,131Polynucleotides Encoding Death Domain-Containing RECEPTOR-5 (DR5) Binding Molecules
In force
 · High confidence
In forceHigh confidence
US 10,787,520Multimeric Bispecific Binding Molecules Specific for CD20 and CD3
In force
 · High confidence
In forceHigh confidence
10 of 20 patents shown.
Pro members see all 20.
Pro members: see all 20 patents
Also on record, not counted in the 20: 2 patents in force now held by others · 3 patents ended · 4 applications pending · 29 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited